• ResMed has already agreed to sell its underperforming MatrixCare aged care software unit to private equity firm Frazier Healthcare Partners for about US$490 million in cash, marking a shift away from non-core healthcare IT assets.
• This divestment sharpens ResMed’s focus on sleep and breathing health while highlighting how evolving artificial intelligence tools may challenge legacy software business models.
• We’ll now examine how the MatrixCare sale and renewed focus on core sleep health could reshape ResMed’s broader investment narrative.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 30 best rare earth metal stocks of the very few that mine this essential strategic resource.

ResMed Investment Narrative Recap

To own ResMed, you need to believe in a long-term shift toward home-based, connected sleep and breathing care, supported by its devices, masks and software. The MatrixCare sale looks consistent with that focus and, in my view, does not materially change the key near term swing factors, which remain reimbursement and competition from alternative sleep apnea treatments, as well as how quickly clinicians and patients adopt ResMed’s digital, AI-enabled care pathways.

Against this backdrop, the planned sale of MatrixCare to Frazier Healthcare Partners for US$490 million stands out as the most relevant recent development. It refocuses capital and management attention on ResMed’s core sleep and breathing health businesses and on expanding its connected care ecosystem, which many investors see as central to both the main catalyst around digital adoption and the key risk of technology and pricing pressure in respiratory hardware.

Yet while the portfolio looks more focused after MatrixCare, investors should still be aware that reimbursement changes could...

ResMed's narrative projects $6.8 billion revenue and $1.9 billion earnings by 2029.

Uncover how ResMed's forecasts yield a $260.60 fair value, a 28% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts were already cautious, assuming revenue of about US$6.6 billion and earnings of US$1.8 billion by 2029, so this kind of portfolio reshaping and index removal could either reinforce their concerns or prompt a rethink, depending on how you weigh capital returns versus execution risk.

Explore 6 other fair value estimates on ResMed - why the stock might be worth as much as 36% more than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your ResMed research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free ResMed research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate ResMed's overall financial health at a glance.

Interested In Other Possibilities?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
• Capitalize on the AI infrastructure supercycle with our selection of the 52 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.